Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670982 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer
A Phase 2 study, sponsored by Harold J. Burstein, MD, PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00670982: Completed Phase 2 study, sponsored by Harold J. Burstein, MD, PhD.
NCT00670982 is a Phase 2 study that has completed, run by Harold J. Burstein, MD, PhD. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00670982, a Phase 2 study, has completed, sponsored by Harold J. Burstein, MD, PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the effects of the combination of bevacizumab, vinorelbine, and trastuzumab on participants and their cancer.
Primary Outcome
Percentage of patients on study without progression at one year after first treatment on study.The date of progression was defined as the earliest occurence of any of the following events: progressive disease by RECIST v1.0, date of initiation of new anticancer therapy, or death due to any cause. New anticancer therapy was defined as the addition or initiation of any new agent for treatment of cancer not including trastuzumab, vinorelbine or bevacizumab.
Interventions
- DRUG bevacizumab
- DRUG trastuzumab
- DRUG vinorelbine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT00670982 record still lists
NCT00670982 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 3 interventions - of which bevacizumab is the first listed.
NCT00670982 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00670982 about?
NCT00670982 is a clinical study titled "Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer". The purpose of this research study is to determine the effects of the combination of bevacizumab, vinorelbine, and trastuzumab on participants and their cancer.
What is the current status of trial NCT00670982?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2008-05. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00670982?
The interventions under investigation include: bevacizumab (DRUG), trastuzumab (DRUG), vinorelbine (DRUG).
Who is sponsoring clinical trial NCT00670982?
This trial is sponsored by Harold J. Burstein, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00670982's enrollment target sits among peer trials
29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia